
Loading, please wait...

Loading, please wait...

This observational cohort study used US NeuroBlu electronic health record data on 70,257 adults with schizophrenia and type 2 diabetes (mean age 53.1 years) to compare initiation of GLP-1 receptor agonists with non-initiation and with initiation of active glucose-lowering comparators. GLP-1 receptor agonist initiation was associated with a lower risk of psychiatric hospitalisation than non-initiation (weighted HR 0.76; 95% CI 0.71–0.82) and than DPP-4 inhibitor initiation (HR 0.82; 95% CI 0.75–0.90), with a 17% lower risk versus SGLT2 inhibitor initiation. Psychiatric emergency department presentations were 29% lower with GLP-1 receptor agonist initiation compared with non-initiation. The authors concluded that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management, that the findings should be interpreted cautiously, and that future studies should explore GLP-1 receptor agonists in schizophrenia, including in populations without type 2 diabetes.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This observational cohort study used US NeuroBlu electronic health record data on 70,257 adults with schizophrenia and type 2 diabetes (mean age 53.1 years) to compare initiation of GLP-1 receptor agonists with non-initiation and with initiation of active glucose-lowering comparators. GLP-1 receptor agonist initiation was associated with a lower risk of psychiatric hospitalisation than non-initiation (weighted HR 0.76; 95% CI 0.71–0.82) and than DPP-4 inhibitor initiation (HR 0.82; 95% CI 0.75–0.90), with a 17% lower risk versus SGLT2 inhibitor initiation. Psychiatric emergency department presentations were 29% lower with GLP-1 receptor agonist initiation compared with non-initiation. The authors concluded that lower psychiatric acute-care use could be a favourable secondary benefit when GLP-1-based therapies are clinically indicated for metabolic management, that the findings should be interpreted cautiously, and that future studies should explore GLP-1 receptor agonists in schizophrenia, including in populations without type 2 diabetes.
Today

The 2025 Australian meningococcal surveillance report shows a 13% decline in invasive meningococcal disease notifications to 118 cases. Genogroup B accounted for 82.2% of typed infections, predominantly impacting infants and young adults, highlighting critical vaccination and rapid diagnostic imperatives.
Today

Doctors at AIIMS New Delhi have achieved a historic milestone by performing India's first open prenatal myelomeningocele repair on a 25-week unborn fetus. This landmark multidisciplinary procedure provides vital neuroprotective benefits, lowers hydrocephalus risks, and transforms maternal-fetal medicine nationwide.
Today

The ACE-PAS registry evaluated 21,612 patients fitted with the ASSURE wearable cardioverter defibrillator. The study demonstrated a 100% ventricular arrhythmia conversion rate, an inappropriate shock incidence of 0.0065 per patient-month, and high daily compliance of 23.1 hours, confirming real-world safety.
Today

A clinical overview of resveratrol supplementation in mitigating exercise-induced muscle damage. This narrative review explores physiological mechanisms, reductions in soreness markers like creatine kinase, dosage strategies, and bioavailability enhancements for sports medicine and nutrition practitioners.
Today

Childhood insulinoma is a rare cause of recurrent hyperinsulinemic hypoglycemia that often eludes early diagnosis. Advanced GLP-1 receptor-targeted PET/CT imaging using 68Ga-exendin-4 complements anatomic MRI to localize occult pancreatic lesions, facilitating focused, curative surgical enucleation.
Today